The target audience for this initiative is Hematology/Oncology physicians, nurses, NPs, and PAs; and pharmacists involved in the diagnosis and treatment of patients with multiple myeloma.
Multiple myeloma (MM) is one of the most common hematologic malignancies in adults and is the most common hematologic malignancy in Black patients. The incidence of MM in the black population is 2-3 times higher than in white patients however, the vast majority of MM clinical trials are conducted on a predominantly white population, resulting in a lack of data regarding MM treatment in Black patients.
Our panel of expert Hematology/Oncology faculty convene a patient focus group-informed interactive video discussion emphasizing the treatment and clinical research disparities among Black and underserved patients. The focus groups were comprised of diverse groups of MM patients currently being treated at Boston Medical Center.
The goals of our educational program are to address existing knowledge gaps related to the racial disparities which impact MM therapy and clinical trial inclusion; highlight ongoing inequities; and provide guidance so that healthcare clinicians can more effectively and equitably treat patients with MM.
For additional education on this topic, please find a second complementary enduring activity linked below which further dives into the results of the focus groups via a moderated panel discussion of the interprofessional care team.
At the conclusion of this activity the participants will be better able to:
Discuss health inequities and racial disparities in multiple myeloma
Describe racially unique adverse drug events associated with treatment for black patients with multiple myeloma
Discuss multiple myeloma treatment risks with black patients to support shared decision-making regarding treatment and manage expectations
Develop strategies to mitigate the multiple barriers to clinical trial enrollment and appropriate clinical care in black and underserved patients with multiple myeloma
Identify appropriate use of BCMA-targeted therapies for all patient populations with multiple myeloma
Boston University Disclosure
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Clinical Care Options Disclosure
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Ms. Arters is a on the advisory board for Rigel.
Dr. Nooka is a consultant for Adaptive, Amgen, Beyond Springs, Bristol-Meyer Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi, SecureBio, and Takeda. He also receives grant/research support from Aduro, Arch Oncology, Amgen, Bristol-Meyer Squibb, Genentech, GlaxoSmithKline, Janssen, Karyopharm, KITE and Takeda.
Dr. Shah receives grant/research support from Alexion, Astrazeneca, Pfizer and Rigel.
Dr. Szalat has no relevant financial relationships to disclose.
Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
The planners and content peer reviewers from Boston University Chobanian & Avedisian School of Medicine and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Michael Burk, BS, Senior Operations Manager, Boston University Chobanian & Avedisian School of Center of Continuing Education, has no relevant financial relationships to disclose.
Christopher Drury, PhD, consultant medical editor, , has no relevant financial relationships to disclose.
Jessica Jeune, RN, Nurse Course Advisor, Planning Committee, has no relevant financial relationships to disclose.
Natalie Sanfratello, MPH, CHCP, Senior Program Manager, Boston University Chobanian & Avedisian School of Center of Continuing Education, has no relevant financial relationships to disclose.
Instructions for CME and CNE Credit Hours
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credit™ and nurses are entitled to receive 1 CNE contact hours, all of which is eligible for pharmacology credit. Statements of credit will be available to print immediately.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Boston University Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Clinical Care Options Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Boston University Chobanian & Avedisian School of Medicine designates this Enduring Material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Nursing Contact Hours: 1.0 of which 1.0 is eligible for pharmacology credit
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-143-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate/Physician Assistant Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until May 30, 2024. PAs should only claim credit commensurate with the extent of their participation.